{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"117","value":"0.603"},{"groupId":"OG001","value":"0.869"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. Accumulation ratio for C-EOI was calculated as C-EOI at the visit divided by C-EOI at Cycle 1.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic population. Only those participants with data available at specified time points have been analyzed. Values were not calculated for some cycles since there were no sufficient data.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Cycle 2, Cycle 3, Cycle 6, Cycle 9 and Cycle 12","title":"Part 1: Observed Accumulation Ratio of C-EOI (R(C-EOI)) Following Repeat Dose Administration of Belantamab Mafodotin (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"Ratio"}